UKs MHRA renews EAMS Scientific Opinion for Santheras Idebenone in Duchenne Muscular Dystrophy

UK’s MHRA renews EAMS Scientific Opinion for Santhera’s Idebenone in Duchenne Muscular Dystrophy

01:09 EDT 24 Jun 2019 | Biotech 365

Pratteln, Switzerland, June 24, 2019 – Santhera Pharmaceuticals (SIX: SANN) announces that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed for a further year the Early Access to Medicines Scheme (EAMS) scientific opinion for idebenone for patients with Duchenne … Continue reading →

More From BioPortfolio on "UK’s MHRA renews EAMS Scientific Opinion for Santhera’s Idebenone in Duchenne Muscular Dystrophy"